New pharmaceuticals in inflammatory bowel disease

Michał Łodyga; Piotr Eder; Witold Bartnik; Maciej Gonciarz; Maria Kłopocka; Krzysztof Linke; Ewa Małecka-Panas; Piotr Radwan; Grażyna Rydzewska

doi:10.5114/pg.2015.52702

eISSN: 1897-4317
ISSN: 1895-5770

Gastroenterology Review/Przegląd Gastroenterologiczny

Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

2/2015
vol. 10

Send email

Copy url:

abstract:

Special paper

New pharmaceuticals in inflammatory bowel disease

Michał Łodyga

,

Piotr Eder

,

Witold Bartnik

,

Maciej Gonciarz

,

Maria Kłopocka

,

Krzysztof Linke

,

Ewa Małecka-Panas

,

Piotr Radwan

,

Grażyna Rydzewska

Prz Gastroenterol 2015; 10 (2): 57–60

DOI: https://doi.org/10.5114/pg.2015.52702

Online publish date: 2015/07/01

View full text Get citation

PlumX metrics:

This paper complements the previously published Guidelines of the Working Group of the Polish Society of Gastroenterology and former National Consultant in Gastroenterology regarding the management of patients with Crohn’s disease and ulcerative colitis. Attention was focused on the new pharmaceutical recently registered for inflammatory bowel disease treatment.

keywords:

New pharmaceuticals in inflammatory bowel disease

Michał Łodyga , Piotr Eder , Witold Bartnik , Maciej Gonciarz , Maria Kłopocka , Krzysztof Linke , Ewa Małecka-Panas , Piotr Radwan , Grażyna Rydzewska

Crohn’s disease, ulcerative colitis, budesonide MMX, golimumab, vedolizumab

Michał Łodyga

,

Piotr Eder

,

Witold Bartnik

,

Maciej Gonciarz

,

Maria Kłopocka

,

Krzysztof Linke

,

Ewa Małecka-Panas

,

Piotr Radwan

,

Grażyna Rydzewska